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Objectives. The Probucol Angioplasty Restenosis Trial was a
prospective, randomized, controlled study that investigated the
effectiveness of probucol therapy in reducing the rate of restenosis
after percutaneous transluminal coronary angioplasty (PTCA).
Background. Antioxidants have an inhibitory effect on smooth
muscle cell growth in experiments in vitro and in vivo, which
suggests a possible pharmacologic effect on restenosis after PTCA.
Methods. One hundred one patients were randomly assigned to
receive 1,000 mg/day of probucol or control (no lipid-lowering)
therapy 4 weeks before PTCA. After 4 weeks of premedication,
both groups underwent PTCA. Probucol was continued until
follow-up angiography 24 weeks after PTCA. Angiographic results
were analyzed at a core laboratory by quantitative coronary
angiography.
Results. Dilation was successful in 46 of 50 patients in the
probucol group and 45 of 51 in the control group. At follow-up
angiography 24 weeks after angioplasty, angiographic restenosis
occurred in 9 (23%) of 40 patients in the probucol group and 22
(58%) of 38 in the control group (p 5 0.001). Minimal lumen
diameter was 1.49 6 0.75 mm (mean 6 SD) in the probucol group
and 1.13 6 0.65 mm in the control group (p 5 0.02). Percent
diameter stenosis at follow-up angiography in the probucol group
was significantly lower than that in the control group (43.9% vs.
56.4%, p 5 0.009). The late loss was 0.37 6 0.69 mm in the
probucol group and 0.60 6 0.62 mm in the control group (p 5
0.13). The loss/gain ratio was 0.32 6 0.74 in the probucol group
and 0.56 6 0.81 in the control group (p 5 0.059). Net gain was
greater in the probucol group than in the control group (0.77 6
0.70 vs. 0.48 6 0.59 mm, p 5 0.053).
Conclusions. Probucol administered beginning 4 weeks before
PTCA appears to reduce restenosis rates.
(J Am Coll Cardiol 1997;30:855–62)
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Restenosis after percutaneous transluminal coronary angio-
plasty (PTCA) is still a major clinical problem. It occurs in 30%
to 50% of patients who undergo PTCA and limits its long-term
success (1–3). Although many clinical trials with lipid-lowering
drugs, angiotensin-converting enzyme inhibitors and anti-
inflammatory drugs have been conducted to resolve this phe-
nomenon, no effective agent has been definitively reported
(4–7). Intravascular stenting has been shown to have a prom-
ising effect on restenosis; however, its application is somewhat
limited, and long-term efficacy and cost-effectiveness are still
uncertain (8,9). Recent epidemiologic studies (10–12) have
suggested an inverse relation between coronary artery disease
mortality and the intake of antioxidants, such as vitamin E and
beta-carotine. There is considerable evidence that antioxidants
reduce experimental atherosclerosis in animal models (13–15).
Antioxidants also have an inhibitory effect on smooth muscle
cell growth in experiments in vitro (16,17) and in vivo (18,19).
This finding suggests a possible preventive effect of antioxi-
dants on restenosis after PTCA (20). Probucol has been shown
to have antioxidant properties as well as lipid-lowering effects
(21). In animal models, probucol showed a beneficial effect on
restenosis (18). In addition, the results of a pilot study of the
Probucol Angioplasty Restenosis Trial (PART) (22), indicated
a preventive effect of probucol on restenosis. PART was
designed to investigate the preventive effect of probucol on
restenosis after PTCA in a prospective, randomized fashion.
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Methods
Patients and study design. Between July 1992 and Septem-
ber 1994, 101 patients were enrolled from the nine participat-
ing institutions in this prospective, randomized, controlled
trial. Eligible criteria for enrollment were 1) stable clinical
symptoms, allowing elective PTCA to be scheduled 4 weeks
after enrollment; 2) no previous PTCA of the index lesion; and
3) informed consent. Patients with acute coronary syndromes
or familial hypercholesterolemia were excluded. Lesions of
previous PTCA, total occlusion, infarct-related lesions, or
lesions in saphenous vein grafts were also excluded. Eligible
patients were randomly assigned to receive probucol
(1,000 mg/day [probucol group]) or no lipid-lowering therapy
(control group). Randomization was undertaken by minimiza-
tion method controlling for the following four factors: PTCA
target segment, total cholesterol level, age and participating
institution. The patients returned 4 weeks after randomization
for PTCA. If the PTCA was successful, the medication was
continued until follow-up angiography 24 weeks later. PTCA
success was defined by $20% reduction in stenosis and
immediate post-PTCA diameter stenosis ,50%.
Lipid and blood chemistry measurements. Blood samples
were taken at the time of enrollment, PTCA and follow-up
angiography for measurement of total cholesterol, triglycer-
ides, high density lipoprotein (HDL) cholesterol and lipopro-
tein(a) [Lp(a)] levels. Low density lipoprotein (LDL) choles-
terol levels were determined by the Freidewald formula (23).
Angiographic method. Cardiac catheterization and PTCA
were performed according to the standard technique. Only
conventional balloon angioplasty was allowed for this study.
The technical aspects of the procedure, including the choice of
balloon, duration of inflation and pressure were determined by
the individual operators. Coronary angiograms were obtained
before and after PTCA and at follow-up angiography at 24
weeks. Angiograms were obtained in multiple projections after
intracoronary injections of 2 mg of isosorbide dinitrate. All
projections of the initial angiograms were repeated at follow-
up. The optimal views of the target lesions from all technically
suitable angiograms were analyzed by quantitative coronary
angiography using the Kontron Cardio 500. A single index
lesion/patient was identified at enrollment and used for the
primary end-point analysis. All angiographic analyses were
performed at a core laboratory whose staff had no knowledge
of the treatment allocation and did not have access to clinical
data.
Quantitative measurements were calibrated using the guid-
ing catheter as the reference dimension. The absolute values
for the minimal lumen diameter as well as the reference vessel
diameter were measured. Intraobserver reliability was assessed
by repeated measurements of 32 stenotic regions by a single
observer. Intraobserver reliability was 0.99 (with a lower limit
of the 95% confidence interval [CI] of 0.96). The 95% pre-
diction interval between the repeated measurement was
60.14 mm. Interobserver variability was assessed by measure-
ments of 32 stenotic regions by two independent observers.
Interobserver reliability was 0.98 (with a lower limit of the 95%
CI of 0.96). The 95% prediction interval between measure-
ments was 60.21 mm at the core laboratory.
Follow-up evaluation. Patients returned for outpatient
evaluation every month. Clinical assessment, including cardiac
status, electrocardiography and assessment of drug compli-
ance, was performed at each visit. Follow-up angiography was
performed during the 24 weeks of follow-up for recurrence of
ischemic symptoms and in all patients at 24 weeks after PTCA.
If a follow-up angiogram was indicated at 16 weeks or later, no
repeat angiogram was requested at 24 weeks. If a recurrent
symptom required repeat PTCA at an earlier time, the angio-
gram before repeat PTCA was used for the analysis. In
addition to angiographic reevaluation, each patient was eval-
uated for clinical events, including repeat PTCA, coronary
artery bypass graft surgery (CABG), acute myocardial infarc-
tion and death.
End points. The primary end point of this trial was the
restenosis rate at follow-up angiography. Restenosis was de-
fined as recurrent lumen diameter stenosis .50% at follow-up
angiography, as determined by quantitative coronary angiog-
raphy (24). Secondary end points were restenosis rate on the
basis of loss of $50% of the initial diameter gain at the index
lesion between post-PTCA and 24-week follow-up (late loss),
percent diameter stenosis, minimal lumen diameter at
follow-up angiography and the ratio of late loss to initial gain
for the index lesion. Clinical events during the follow-up period
were also analyzed. Clinical events included the need for an
additional revascularization procedure for restenosis, myocar-
dial infarction or cardiac-related death. Myocardial infarction
was defined as the occurrence of typical symptoms, electrocar-
diographic changes and creatine kinase elevation to twice the
upper limit of normal.
Data collection and statistical analysis. All data were
recorded on standardized forms and were entered into a data
base. The data are expressed as proportions or as mean
value 6 SD. Differences in categoric variables between the
probucol and control groups were analyzed by the chi-square
test or the Fisher exact test. Continuous variables were ana-
lyzed with the Student t test. We used two-tailed p values for all
statistical testing in the present study. For multivariate analy-
sis, logistic regression analysis was used to determine the
factors independently related to restenosis. Selected variables
were those that demonstrated significant association with
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
PART 5 Probucol Angioplasty Restenosis Trial
PDGF 5 platelet-derived growth factor
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restenosis by univariate analysis. The present study, with a
sample of 100 patients evenly divided between two groups, had
a power of 80% and a significance of 95% for detecting the
reduction of restenosis rate from 45% to 20%.
Results
Fifty patients were randomly assigned to the probucol
group and 51 to the control group. PTCA was successful in 40
of 50 patients in the probucol group and 38 of 51 in the control
group 4 weeks after enrollment and underwent follow-up
angiography at 24 weeks after PTCA (p 5 NS). Of 23 patients
who were excluded from the analysis, 5 (2 in the probucol
group, and 3 in the control group) were treated medically and
did not undergo PTCA; PTCA was unsuccessful in 6 (3 in each
group); and 12 (5 in the probucol group, 7 in the control
group) did not undergo follow-up angiography.
Baseline characteristics. Baseline clinical characteristics
were similar in the two study groups (Table 1). Mean age in
both groups was 60 years, and 64 patients were male. The
prevalence of diabetes mellitus, current smoker status, previ-
ous myocardial infarction and previous PTCA and CABG were
similar in both groups, but hypertension was more frequent in
the probucol group. Among the angiographic variables, there
were no significant differences between the two groups in
number of diseased vessels, location of the index lesion and
lesion morphology (25). In the comparison of patients who had
follow-up angiography versus those who did not, no statistically
significant differences were observed, but patients without
follow-up angiography tended to be older than those with
follow-up angiography.
Lipid profile and response to probucol. Blood lipid levels
at enrollment, at PTCA and at follow-up angiography are
shown in Table 2. LDL and HDL cholesterol and Lp(a) levels
Table 1. Baseline Clinical Characteristics of Study Patients
With F/U Angio Without F/U Angio
Probucol Group
(n 5 40)
Control Group
(n 5 38)
p
Value*
Combined
(n 5 12)
p
Value†
Mean age (yr) 60 6 9 60 6 9 NS 64 6 8 NS
Male 33 (83) 31 (82) NS 10 (83) NS
Hypertension 24 (60) 12 (32) , 0.05 7 (58) NS
Diabetes mellitus 10 (25) 13 (34) NS 5 (42) NS
Current smoker 24 (60) 20 (53) NS 6 (50) NS
Previous MI 7 (18) 9 (24) NS 3 (25) NS
Previous PTCA 3 (8) 4 (11) NS 0 (0) NS
Previous CABG 3 (8) 5 (13) NS 1 (8) NS
No. of diseased vessels
One 22 (55) 19 (50) 6 (50)
Two 14 (35) 14 (37) NS 5 (42) NS
Three 4 (10) 5 (13) 1 (8)
Vessel dilated
RCA 7 (18) 7 (18) 2 (17)
LAD 24 (60) 18 (47) NS 3 (25) NS
LCx 9 (23) 13 (34) 7 (58)
ACC/AHA lesion type (25)
A 19 (48) 17 (45) NS 5 (42) NS
B 21 (52) 21 (55) 7 (58)
* Probucol group versus control group. †Patients with versus without follow-up angiography (F/U angio). Data
presented are mean value 6 SD or number (%) of patients; ACC/AHA 5 American College of Cardiology/American
Heart Association; CABG 5 coronary artery bypass graft surgery; LAD 5 left anterior descending coronary artery;
LCx 5 left circumflex coronary artery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty; RCA 5 right coronary artery.
Table 2. Lipid Levels in Response to Probucol Therapy
Probucol
Group
Control
Group
p
Value
Baseline
LDL-C 145 6 30 132 6 41 0.157
HDL-C 37 6 13 35 6 10 0.456
TGs 132 6 55 210 6 198 0.024
Lp(a) 22 6 23 26 6 25 0.521
PTCA
LDL-C 116 6 35 137 6 35 0.030
HDL-C 25 6 9.4 35 6 11 0.0001
TGs 112 6 55 140 6 114 0.183
Lp(a) 20 6 21 24 6 23 0.525
F/U angio
LDL-C 125 6 35 137 6 34 0.181
HDL-C 29 6 15 39 6 12 0.002
TGs 125 6 60 153 6 97 0.123
Lp(a) 21 6 21 24 6 23 0.517
Data presented are mean value 6 SD (mg/dl). HDL-C 5 high density
lipoprotein cholesterol; LDL-C 5 low density lipoprotein cholesterol; Lp(a) 5
lipoprotein(a); TGs 5 triglycerides; other abbreviations as in Table 1.
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were not different between the probucol and control groups at
enrollment. Triglyceride levels in the control group were
significantly higher than those in the probucol group. LDL and
HDL cholesterol levels decreased significantly by the time of
PTCA in the probucol group, and the decreases largely
persisted until follow-up angiography. Triglyceride and Lp(a)
levels did not change significantly. In the control group, there
was no significant change in any lipid levels. At PTCA, LDL
and HDL cholesterol levels in the probucol group were
significantly lower than those in the control group. At follow-
up, HDL cholesterol levels were also lower in the probucol
group than in the control group.
Quantitative coronary angiography. The results of angio-
graphic assessment of the index lesion are presented in Table
3. There were no significant differences between the probucol
and control groups in percent diameter stenosis and minimal
lumen diameter before and after angioplasty. Percent diameter
stenosis at follow-up in the probucol group was significantly
lower than that in the control group (43.9% vs. 56.4%, p 5
0.009). Minimal lumen diameter at follow-up angiography was
1.49 6 0.75 mm in the probucol group and 1.13 6 0.65 mm in
the control group (p 5 0.02). The lumen diameter of the
reference segment was not different between the two groups
throughout the trial. The initial gain was 1.14 6 0.42 mm in the
probucol group and 1.08 6 0.60 mm in the control group (p 5
NS). Late loss was 0.37 6 0.69 mm in the probucol group and
0.60 6 0.62 mm in the control group (p 5 0.13). The loss/gain
ratio was 0.32 6 0.77 in the probucol group and 0.56 6 0.81 in
the control group (p 5 0.059). Net gain was greater in the
probucol group than in the control group (0.77 6 0.70 vs.
0.48 6 0.59 mm, p 5 0.053). The cumulative frequency curve
of percent diameter stenosis and minimal lumen diameter are
shown in Figures 1 and 2, respectively. A significantly lower
percent diameter stenosis was demonstrated in the probucol
group; however, the difference between the two groups was less
pronounced for minimal lumen diameter. Accordingly, the
restenosis rate, which was defined as recurrent lumen diameter
stenosis .50% in the dilated segment, was 23% (9 of 40
patients) in the probucol group and 58% (22 of 38 patients) in
the control group (p 5 0.001). However, the restenosis rate
based on the criteria of loss of initial gain .50% was 30% (12
patients) in the probucol group and 50% (19 patients) in the
control group (p 5 0.07) (Fig. 3).
Clinical outcome. All patients were followed up until an-
giographic restudy for cardiac-related death, acute myocardial
infarction or repeat revascularization. No cardiac-related
Figure 1. Cumulative distribution curves for
percent diameter stenosis of the index lesion
before and after PTCA and at follow-up
angiography at 24 weeks. Thin curves 5 con-
trol group; thick curves 5 probucol group.
Table 3. Quantitative Angiographic Analysis of Index Lesion
Probucol
Group
Control
Group
p
Value
% DS
Before PTCA 74 6 9.8 77 6 10.6 0.22
After PTCA 29.2 6 9.3 33.7 6 11.8 0.12
F/U angio 43.9 6 20.0 56.4 6 21.2 0.009
MLD (mm)
Before PTCA 0.72 6 0.35 0.64 6 0.34 0.32
After PTCA 1.86 6 0.55 1.72 6 0.48 0.24
F/U angio 1.49 6 0.75 1.13 6 0.65 0.02
RLD (mm)
Before PTCA 2.7 6 0.71 2.8 6 0.83 0.57
After PTCA 2.7 6 0.86 2.6 6 5.5 0.54
F/U angio 2.6 6 0.84 2.6 6 0.70 0.65
Initial gain (mm) 1.14 6 0.42 1.08 6 0.60 0.59
Late loss (mm) 0.37 6 0.69 0.60 6 0.62 0.13
Loss/gain ratio 0.32 6 0.77 0.56 6 0.81 0.059
Net gain (mm) 0.77 6 0.70 0.48 6 0.59 0.053
Data presented are mean value 6 SD. MLD 5 minimal lumen diameter;
RLD 5 reference lumen diameter; %DS 5 percent diameter stenosis; other
abbreviations as in Table 1.
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death or acute myocardial infarction occurred during the
6-month follow-up period in either group. Repeat angioplasty
was required in 6 patients in the probucol group (index lesion
in 4, nonindex lesion in 2) and in 11 in the control group (index
lesion in 10, nonindex lesion in 1). One patient in each group
underwent CABG. Thus, target lesion revascularization (re-
peat PTCA and CABG) was performed in 7 (15.2%) of 46
patients in the probucol group and 12 (26.7%) of 45 in the
control group by 24 weeks (p 5 NS).
Factors related to restenosis: univariate and multivariate
analysis. By univariate analysis, six factors were found to be
related to restenosis (Table 4): The minimal lumen diameter 1)
before and 2) after angioplasty in patients with restenosis was
significantly smaller than that in patients without restenosis. 3)
The lumen diameter of the reference artery in patients without
restenosis was significantly larger than that in patients with
restenosis. 4) The change in HDL cholesterol levels was
significantly greater in patients without than in those with
restenosis. 5) The proportion of patients who had taken
probucol was significantly higher in those without restenosis
than in those with restenosis 6) Type B lesions were more
frequent in patients with than in those without restenosis.
Changes in LDL cholesterol levels were not different between
the two groups.
By multiple logistic regression analysis (Table 5), the use of
probucol contributed significantly in reducing the rate of
restenosis independent of LDL and HDL cholesterol reduc-
tion. The odds ratio of restenosis with probucol was 0.2 (95%
CI of 0.04 to 0.92). Other significant variables for predicting
restenosis were reference diameter and the presence of a type
B lesion.
Discussion
The PART study investigated the effectiveness of probucol
therapy in reducing restenosis rates after PTCA. Angiographic
Figure 2. Cumulative distribution curves
for minimal lumen diameter of the index
lesion before and after PTCA and at
follow-up angiography at 24 weeks. Thin
curves 5 control group; thick curves 5
probucol group.
Figure 3. Restenosis rate of index lesion in each treat-
ment group. Left panel, Restenosis defined as percent
stenosis .50% at follow-up angiography. Right panel,
Loss of $50% of the initial diameter gain in the index
lesion between PTCA and 24-week follow-up angiogra-
phy.
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restenosis occurred in 23% of patients in the probucol group
and in 57% of those in the control group (p 5 0.001). The
restenosis rate in the control group was somewhat higher than
expected in the present study; however, the high proportion of
type B lesions may be responsible for this phenomenon. At
follow-up angiography, minimal lumen diameter and percent
diameter stenosis in the probucol group were significantly
greater than that in the control group. The loss/gain ratio
tended to be lower, and net gain was found to be greater, in the
probucol group than in the control group. Although some
angiographic end points were of borderline significance, the
reduced restenosis rate by probucol in the present study was
encouraging.
There are few trials in which antioxidants have been used
for preventing restenosis. In the study by (26) DeMaio et al.,
patients undergoing angioplasty received 1,200 IU of vitamin
E/day starting on the day of angioplasty, and a trend toward a
reduction in restenosis was seen, as measured by repeat
angiography and thallium or exercise testing. We previously
demonstrated (22) the favorable effect on PTCA restenosis of
probucol pretreatment for 4 weeks compared with short-term
pretreatment with probucol or short- or long-term pretreat-
ment with pravastatin. Setsuda et al. (27) demonstrated a
significant reduction in the restenosis rate with probucol given
6 days before PTCA compared with that for dipyridamole.
However, quantitative coronary angiography was not used in
that study. Watanabe et al. (28) demonstrated a significant
reduction in the restenosis rate after PTCA when probucol was
administered 7 days before the procedure. Tardif et al. (29)
recently reported significant reduction in late lumen loss by
probucol in their Multivitamins and Probucol Study.
Mechanism of antioxidant action. The process of resteno-
sis after PTCA involves smooth muscle cell proliferation,
extracellular matrix formation and vascular remodeling (30).
Although the details of the mechanism are still unclear, there
is considerable evidence that suggests that oxidative stress
plays an important role in the restenosis process. Reactive
oxygen species and lipid oxidative products induced by balloon
injury have been reported (31) to stimulate the expression of
early-response genes c-fos and c-myc and smooth muscle cell
proliferation. It has been demonstrated (32) that lipid oxida-
tion products can alter growth factor production, which could
also influence smooth muscle cell proliferation. Oxidized LDL
has been shown (33) to be a chemoattractant for smooth
muscle cells and a stimulant of smooth muscle cell prolifera-
tion. It enhances platelet-derived growth factor (PDGF)-AA
gene expression and PDGF receptor expression in vascular
smooth muscle cell (34). It is therefore possible that lipid
oxidation products induced by balloon vascular injury poten-
tially promote smooth muscle cell proliferation and extracel-
lular matrix formation (20).
Probucol reduced the levels of LDL and HDL cholesterol,
and the decrease in HDL cholesterol was significantly greater
in patients without than in those with restenosis. The reduction
in HDL cholesterol by probucol may reflect an increase in
reverse cholesterol transport and, consequently, its antiathero-
genic effect (35). However, because probucol reduced the
restenosis rate independently of its LDL or HDL cholesterol-
lowering effect in the present study, the mechanism of prevent-
ing restenosis appears to be independent of its lipid-lowering
effect. Probucol has a powerful antioxidant property that has
been shown (18,21) to suppress intimal thickening after bal-
loon injury in animal models. It has a superoxide free radical
scavenging effect and inhibits the production of PDGF and
interleukin-1 (36–39). It protects LDL from oxidation, which
also potentially reduces smooth muscle cell proliferation. By
the mechanisms described here, probucol appears to have
reduced the restenosis rate in the present study. Recently,
Nunes at al. (40) demonstrated that the combination of
vitamins E and C improved vascular response to injury because
of a beneficial effect on vascular remodeling in the swine
coronary injury model. It is also possible that probucol reduced
the restenosis rate by altering the vascular remodeling process
in the present study.
Need for probucol pretreatment. Pretreatment with probu-
col 4 weeks before PTCA was used in the present trial. In the
process of restenosis, the initiation of smooth muscle cell
proliferation and its signal transduction begins at the time of
balloon injury. It has been proposed (20) that pretreatment
that can achieve adequate plasma levels of drug is necessary to
inhibit this initial promotion. Reaven et al. (41) indicated that
probucol requires several months of oral administration to
achieve adequate plasma levels and sufficient antioxidant pro-
tection in humans. In a pilot study we previously demonstrated
(22) that the preventive effect of probucol required 4 weeks of
pretreatment. Adequate duration of pretreatment allows pro-
Table 4. Univariate Analysis for Prediction of Restenosis
Restenosis
No
Restenosis
p
Value
Pre-PTCA MLD (mm) 0.58 6 0.31 0.75 6 0.35 0.026
Post-PTCA MLD (mm) 1.63 6 0.47 1.90 6 0.52 0.024
Pre-PTCA RLD (mm) 2.49 6 0.66 2.90 6 0.80 0.02
HDL-C decrease (mg/dl) 1.21 6 11.4 5.22 6 9.95 0.014
Probucol 15/46 23/32 0.00064
ACC/AHA type B lesion (25) 22/30 21/46 0.017
Data presented are mean value 6 SD or number of patients. Abbreviations
as in Tables 1 to 3.
Table 5. Multivariate Analysis for Prediction of Restenosis
R OR (95% CI) p Value
Probucol 20.16 0.20 (0.04–0.92) 0.04
HDL-C decrease 0.00 0.98 (0.92–1.05) 0.61
Pre-PTCA MLD 0.00 0.42 (0.05–3.72) 0.43
Post-PTCA MLD 0.00 1.03 (0.09–11.11) 0.98
RLD 20.19 0.15 (0.03–0.76) 0.02
ACC/AHA type B lesion (25) 0.16 4.32 (1.12–16.66) 0.03
CI 5 confidence interval; OR 5 odds ratio; R 5 partial correlation
coefficient; other abbreviations as in Tables 1 to 3.
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bucol to bind LDL and to be incorporated in the cellular
membrane.
Limitation of the present study. The small sample size in
the present study resulted in a borderline effect of probucol on
quantitative coronary angiography, although probucol demon-
strated a significant preventive effect on the restenosis rate
when a dichotomous definition was used. Further investigation
is warranted to confirm the effect of probucol in a large trial.
The need for 4 weeks of pretreatment with probucol limits the
clinical usefulness of the drug. Because it is usually difficult to
wait 4 weeks for PTCA, a practical method for achieving an
adequate plasma levels of probucol in a shorter time period
should be studied. Lack of placebo in the control group was
another limitation. However, the end point of quantitative
coronary angiography allowed us to obtain unbiased analysis
results.
Conclusions. Probucol administered beginning 4 weeks
before PTCA reduced restenosis rates. Its preventive effect
appears to be independent of lipid-lowering effects. A trial with
a larger sample size is warranted to confirm this preventive
effect.
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